Abstract:Background: CD47-targeted immune checkpoint inhibitors have shown potent anti-tumor efficacy in several malignant tumors. However, glioblastoma, one of the most malignant brain tumors in the central nervous system (CNS), was still a challenge for CD47-targeted immunotherapy. Methods: SIRPα-Fc, a CD47-targeted fusion protein, was employed to investigate the anti-tumor efficacy of blocking CD47-SIRPα axis alone or combined with autophagy depletion in glioblastoma. Confocal microscopy, transmission electron microscopy and western blot were used to detect autophagy. Glioblastoma xenograft tumors were established to investigate the synergistic anti-tumor effect of simultaneously blocking CD47-SIRPα axis and autophagy in glioblastoma. Syngeneic immunocompetent glioblastoma models were established to detect the role of adaptive immune response in SIRPα-Fc-treated glioblastoma. Results: SIRPα-Fc has potent anti-glioblastoma efficacy via increasing macrophages phagocytosis and cytotoxicity against glioblastoma cells. Meanwhile, autophagy and autophagic flux were markedly triggered by SIRPα-Fc in glioblastoma cells through inactivation of Akt/mTOR. Importantly, abolishment of the autophagy by pharmacological inhibitors or siRNA enhanced SIRPα-Fc-induced macrophage phagocytosis and cytotoxicity against glioblastoma cells. Simultaneously blocking CD47-SIRPα axis and autophagy increased macrophages infiltration and tumor cell apoptosis, eliciting enhanced anti-glioblastoma efficacy and prolonged survival of tumor-bearing mice compared with treatment with SIRPα-Fc alone. Furthermore, adaptive immune responses, mainly including CD8+ T cells, were also involved in the anti-glioblastoma efficacy of SIRPα-Fc. Conclusions: Our data revealed that SIRPα-Fc could elicit potent anti-glioblastoma efficacy, combined with autophagy inhibition significantly enhanced the anti-glioblastoma efficacy, which highlighted a potential therapeutic approach for glioblastoma through disrupting CD47-SIRPα axis alone or combined with autophagy depletion. Legal entity responsible for the study: Fudan University Funding: None Disclosure: All authors have declared no conflicts of interest.

Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

Disrupting CD47-SIRPα Axis Alone or Combined with Autophagy Depletion for the Therapy of Glioblastoma.

Novel and Promising Therapeutic Approaches for Glioblastoma: Blocking CD47-SIRPα Axis Alone or Combined with Autophagy Depletion

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells

Dual Genes Manipulation Enhanced Chemotherapy Potentiates Antitumor Immunity Based on Extracellular Vesicle System for Glioblastoma Treatment

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Surgical Debulking Promotes Recruitment of Macrophages and Triggers Glioblastoma Phagocytosis in Combination with CD47 Blocking Immunotherapy.

Phosphatase and Tensin Homolog Reconstruction and Vascular Endothelial Growth Factor Knockdown Synergistically Inhibit the Growth of Glioblastoma

Cnsc-60. Synergistic Immunomodulation Through Dual Antibody Therapy Targeting Cd47 And Cd24 For Enhanced Antitumor Immunity In Glioblastoma

Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors

AB042. Combined Anti-Pd-l1 and Anti-Vegfr2 Therapy Promotes the Antitumor Immune Response in Glioblastoma Multiforme by Reprogramming Tumor Microenvironment

Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth

Dual Inhibition of FGFR1 and FAK As a Novel Glioblastoma Targeted Therapy

Autophagy inhibition signals through senescence to promote tumor suppression

A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis

TMIC-07. DUAL INHIBITION OF ANG-2 AND VEGF RECEPTORS NORMALIZES TUMOR VASCULATURE AND PROLONGS SURVIVAL IN GLIOBLASTOMA BY ALTERING MACROPHAGES